Cargando…

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele

Detalles Bibliográficos
Autores principales:	Naidoo, Anushka, Naidoo, Kogieleum, Ramsuran, Veron, Reddy, Millidhashni, Padayatchi, Nesri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574687/ https://www.ncbi.nlm.nih.gov/pubmed/28883739 http://dx.doi.org/10.2147/PGPM.S146787

Ejemplares similares

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
por: Panagopoulos, Periklis, et al.
Publicado: (2017)

Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis
por: Du, Pengqiang, et al.
Publicado: (2019)

Polymorphisms within the SARS-CoV-2 Human Receptor Genes Associate with Variable Disease Outcomes across Ethnicities
por: Adimulam, Theolan, et al.
Publicado: (2023)

Understanding the Profile of Tuberculosis and Human Immunodeficiency Virus Coinfection: Insights from Expanded HIV Surveillance at a Tuberculosis Facility in Durban, South Africa
por: Perumal, Rubeshan, et al.
Publicado: (2014)

TB epidemiology: where are the young women? Know your tuberculosis epidemic, know your response
por: Perumal, Rubeshan, et al.
Publicado: (2018)

HIV-Associated Tuberculosis
por: Naidoo, Kogieleum, et al.
Publicado: (2011)

Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa
por: Padayatchi, Nesri, et al.
Publicado: (2019)

Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field
por: Dookie, Navisha, et al.
Publicado: (2022)

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial
por: Naidoo, Anushka, et al.
Publicado: (2022)

Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care
por: Dookie, Navisha, et al.
Publicado: (2018)

Quality of TB care among people living with HIV: Gaps and solutions
por: Naidoo, Kogieleum, et al.
Publicado: (2019)

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
por: Vardhanabhuti, Saran, et al.
Publicado: (2015)

Analysis of the UGT1A1 Genotype in Hyperbilirubinemia Patients: Differences in Allele Frequency and Distribution
por: Mi, Xiao-xiao, et al.
Publicado: (2019)

Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing
por: Dookie, Navisha, et al.
Publicado: (2020)

Antimicrobial stewardship in South Africa: a scoping review of the published literature
por: Chetty, Sarentha, et al.
Publicado: (2019)

Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Amandito, Radhian, et al.
Publicado: (2019)

Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal
por: Naidoo, Kogieleum, et al.
Publicado: (2018)

Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment
por: Perumal, Rubeshan, et al.
Publicado: (2023)

Commentary: Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Heydari, Mohammad Reza, et al.
Publicado: (2020)

Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency
por: Choe, Pyoeng Gyun, et al.
Publicado: (2010)

Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human
por: van der Mey, Dorina, et al.
Publicado: (2020)

Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol
por: Naidoo, Kogieleum, et al.
Publicado: (2017)

Correction to: Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol
por: Naidoo, Kogieleum, et al.
Publicado: (2019)

Genetic Spectrum of UGT1A1 in Korean Patients with Unconjugated Hyperbilirubinemia
por: Kim, Jin Ju, et al.
Publicado: (2020)

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report
por: Uglietti, Alessia, et al.
Publicado: (2009)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor
por: Saif, Muhammad Wasif, et al.
Publicado: (2016)

Detection of differentially culturable tubercle bacteria in sputum from drug-resistant tuberculosis patients
por: Gordhan, Bhavna G., et al.
Publicado: (2022)

Aetiology, Clinical Presentation, and Outcome of Meningitis in Patients Coinfected with Human Immunodeficiency Virus and Tuberculosis
por: Bhagwan, Smita, et al.
Publicado: (2011)

Clinical significance of the UGT1A1*28 allele detection in HIV-infected patients
por: Kanestri, Veronika, et al.
Publicado: (2014)

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
por: Xu, C-F, et al.
Publicado: (2010)

Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa
por: Rambaran, Santhuri, et al.
Publicado: (2021)

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV
por: Li, Michael, et al.
Publicado: (2020)

Organizational contextual factors that predict success of a quality improvement collaborative approach to enhance integrated HIV-tuberculosis services: a sub-study of the Scaling up TB/HIV Integration trial
por: Gengiah, Santhanalakshmi, et al.
Publicado: (2021)

The Effect of UGT1A1 Promoter Polymorphism in the Development of Hyperbilirubinemia and Cholelithiasis in Hemoglobinopathy Patients
por: AlFadhli, Suad, et al.
Publicado: (2013)

Association of Neonatal Hyperbilirubinemia with UGT1A1 Gene Polymorphisms: A Meta-Analysis
por: Yu, Zibi, et al.
Publicado: (2015)

Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1(-/-) mouse model
por: Vodret, Simone, et al.
Publicado: (2017)

Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia
por: Dorresteijn, Mirrin J., et al.
Publicado: (2023)

High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa
por: Msomi, Nokukhanya, et al.
Publicado: (2020)

Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial
por: Naidoo, Kogieleum, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9pg0ju0ieh9dph7kr4qhke5ads